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Abstract
Introduction Continuous positive airway pressure ventilation
(CPAP) and non-invasive positive pressure ventilation (NPPV)
are accepted treatments in acute cardiogenic pulmonary edema
(ACPE). However, it remains unclear whether NPPV is better
than CPAP in reducing the need for endotracheal intubation
(NETI) rates, mortality and other adverse events. Our aim was to
review the evidence about the efficacy and safety of these two
methods in ACPE management.
Methods We conducted a systematic review and meta-analysis
of randomized controlled trials on the effect of CPAP and/or
NIPV in the treatment of ACPE, considering the outcomes NETI,
mortality and incidence of acute myocardial infarction (AMI). We
searched six electronic databases up to May 2005 without
language restrictions, reviewed references of relevant articles,
hand searched conference proceedings and contacted experts.
Results Of 790 articles identified, 17 were included. In a pooled
analysis, 10 studies of CPAP compared to standard medical
therapy (SMT) showed a significant 22% absolute risk reduction
(ARR) in NETI (95% confidence interval (CI), -34% to -10%)
and 13% in mortality (95%CI, -22% to -5%). Six studies of
NPPV compared to SMT showed an 18% ARR in NETI (95%CI,
-32% to -4%) and 7% in mortality (95%CI, -14% to 0%). Seven
studies of NPPV compared to CPAP showed a non-significant
3% ARR in NETI (95%CI, -4% to 9%) and 2% in mortality
(95%CI, -6% to 10%). None of these methods increased AMI
risk. In a subgroup analysis, NPPV did not lead to better
outcomes than CPAP in studies including more hypercapnic
patients.
Conclusion Robust evidence now supports the use of CPAP
and NPPV in ACPE. Both techniques decrease NETI and
mortality compared to SMT and none shows increased AMI risk.
CPAP should be considered a first line intervention as NPPV did
not show a better efficacy, even in patients with more severe
conditions, and CPAP is cheaper and easier to implement in
clinical practice.
Introduction
The public health burden of heart failure is very high. In the
United States, heart failure is the most frequent cause of hos-
pitalization in persons over 65 years of age [1], and in 2004,
the estimated direct and indirect costs were 25.8 billion dol-
lars [2]. A 4% hospital mortality due to heart failure was
recently reported [3]. This rate increases to 36% in severe
cases needing mechanical ventilation [4].
ACPE = acute cardiogenic pulmonary edema; AMI = acute myocardial infarction; CI = confidence interval; COPD = chronic obstructive pulmonary 
disease; CPAP = continuous positive airway pressure ventilation; ETI = endotracheal intubation; NPPV = non-invasive positive pressure ventilation; 
RCT = randomized controlled trial; SMT = standard medical therapy.Critical Care    Vol 10 No 2    Winck et al.
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During the past 10 years, continuous positive airway pressure
(CPAP) and non-invasive positive pressure ventilation (NPPV)
have gained decisive roles in the management of various forms
of respiratory failure [5][6]. Non-invasive ventilation achieves
physiological improvement and efficacy similar to invasive ven-
tilation [7], and by avoiding endotracheal intubation (ETI)
reduces morbidity and complications [6].
Both NPPV and CPAP have been successfully used in
patients with acute cardiogenic pulmonary edema (ACPE)
[8,9]. A meta-analysis pooling data from three randomized
controlled trials (RCTs) [10], published seven years ago, sup-
ported the efficacy of CPAP in avoiding ETI in ACPE patients,
but showed no evidence of improved survival. Since that pub-
lication, several new RCTs have been published comparing
NPPV, CPAP and standard medical therapy (SMT) in ACPE
patients [11-25]. However, because most of them were small,
several issues remain unresolved. The evidence about the size
and significance of a reduction in mortality and about whether
one technique is superior to the other remains unclear. Clini-
cally important questions about which technique would lead to
better outcomes in more hypercapnic patients [19] and about
the best level of pressure support in NPPV [26] have also
been raised, and may be preventing the wider use of these
technologies.
Concerns have also been raised about safety issues related to
non-invasive ventilation. Mehta and colleagues [25] showed,
in an interim analysis of an RCT, an increased risk of acute
myocardial infarction (AMI) in patients treated with NPPV. Due
to the limited number of patients enrolled, however, those
results were not conclusive, suggesting the need for a critical
analysis of the safety of NPPV and CPAP in the treatment of
ACPE.
A very recent meta-analysis unfortunately addressed only
some of the questions to which clinicians need answers.
Masip and colleagues [27], showed that non-invasive ventila-
tion – jointly considering CPAP and NPPV together as if they
were the same technology – was associated with a 43% rela-
tive risk reduction in mortality and 56% relative risk reduction
in the need for ETI, and found no significant differences in effi-
cacy between those two modalities. An important criticism of
this review is that it presents results for non-invasive ventilation
(pooling CPAP and NPPV together) and consequently double
counting control group patients in three studies (with three
arms), inflating the number of patients included and having
potential impact on the calculated confidence intervals and
conclusions. Moreover, this meta-analysis failed to include two
useful studies (one inappropriately excluded and one not
found). It also did not analyze evidence about differences in
efficacy in the subset of more hypercapnic patients or about
differences related to the level of pressure support in NPPV. It
commented on but did not present relevant data, or thoroughly
analyze, the potentially increased AMI risk associated with
non-invasive ventilation, another issue that concerns clinicians.
Finally, the results of this meta-analysis were presented using
the relative risk scale, which is less easy to translate to prac-
tice and more challenging for clinicians to understand.
The aim of our study was to systematically review the evidence
in order to answer key clinical questions about the efficacy and
safety of CPAP and NPPV in the treatment of patients with
ACPE, considering three different outcomes: the need for ETI;
in-hospital all cause mortality; and incidence of newly devel-
oped AMI. We specifically and separately addressed three dif-
ferent comparisons: CPAP and SMT versus SMT alone; NPPV
and SMT versus SMT alone; and NPPV and SMT versus
CPAP and SMT. Secondary aims were to analyze the impact
of patients' baseline hypercapnia on the efficacy of CPAP and
NPPV and to test a common clinical hypothesis about the
advantage of NPPV when using higher levels of pressure sup-
port ventilation.
Materials and methods
Study design
A systematic review and meta-analysis of RCTs focusing on
the effect of CPAP and NPPV in the treatment of ACPE was
undertaken. The methodological approach included the devel-
opment of selection criteria, definition of search strategies,
quality assessment of the studies, data abstraction and statis-
tical data analysis [28].
Selection criteria
The study selection criteria were defined before data collec-
tion, in order to properly identify high quality studies eligible for
the analysis.
The following inclusion criteria were defined. Patient popula-
tion: adult patients presenting to hospital with ACPE, defined
as existence of dyspnea of sudden onset, increased respira-
tory rate, a compatible physical examination (bilateral crackles
on pulmonary auscultation, elevated jugular venous pressure,
third heart sound on cardiac auscultation), bilateral pulmonary
infiltrates on chest radiograph plus significant hypoxemia.
Study design: prospective randomized parallel trials with inde-
pendent randomization of ACPE patients. Interventions: use of
CPAP (delivered using any device) and medical therapy com-
pared with standard medical therapy alone; use of NPPV (with
any device) and medical therapy compared with standard
medical therapy alone; or use of CPAP and medical therapy
compared with NPPV and medical therapy. Outcomes: need
for ETI as decided by trialists, all-cause mortality and risk of
newly developed AMI after delivery of study interventions.
To improve the internal validity of this meta-analysis, we
decided to consider separately trials of NPPV and CPAP,
because these two methods have different technical, physio-
logical and clinical characteristics. Pooling those two interven-
tions in a single 'non-invasive ventilation' intervention may notAvailable online http://ccforum.com/content/10/2/R69
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be appropriate and could have led to additional heterogeneity
and patient overlap in trials with three arms. Also, trials that
included both acute respiratory failure and ACPE patients [29-
33] were included only if there was independent stratified ran-
domization of therapies for this sub-group.
Search strategy
Our primary method to locate potentially eligible studies was a
computerized literature search in the MEDLINE database,
from inception to May 2005, without any restriction on lan-
guage of publication, using the following search keywords and
MeSH terms: (artificial respiration or continuous positive air-
way pressure or non-invasive positive pressure ventilation or
non-invasive ventilation or non-invasive ventilation) and (pul-
monary edema or pulmonary oedema or congestive heart fail-
ure) and (clinical and trial or clinical trials or clinical trial or
random* or random allocation or therapeutic use). Literature
searches were also undertaken, using the same search key-
words, in the following databases: the American College of
Physicians (ACP) Journal Club Database; the Cochrane Cen-
tral Register of Controlled Trials (CCTR); the Cochrane Data-
base of Systematic Reviews (CDSR); the Digital Academic
Repositories (DARE) Database; and the MetaRegister of Con-
trolled Trials at Current Controlled Trials webpage.
In defining all search strategies we gave priority to formats with
higher sensitivity, in order to increase the probability of identi-
fying all relevant articles.
We also reviewed the references of all relevant articles and
review articles, hand searched abstracts and conference pro-
ceedings of recent relevant congresses and scientific forums
Table 1
General and specific quality criteria
General quality criteria
Sample size (total number of participants)
Randomization allocation concealment (adequate, inadequate or uncertain)
Objective selection criteria for participants:
Yes: if inclusion and exclusion criteria for participants are adequately reported
No: if selection criteria are not reported
Blinding:
Yes: for articles that implemented blinding at any level
No: for articles reporting not being able to implement blinding of interventions at any level
Not reported: for articles that did not make any mention of blinding
Standardization of co-interventions:
Yes: if there was an attempt to standardize treatment and care besides the assigned interventions
No: if no attempt to standardize was applied
Uncertain: if this was not clearly reported
Intention-to-treat analysis (adequate, inadequate or uncertain)
Complete follow-up details (yes, no, not reported)
Outcome definition:
Adequate: if objective criteria for endotracheal intubation were defined
Inadequate: if the criteria were not defined
Uncertain: if application of criteria was unclear
Specific quality criteria
Patient selection criteria (inclusion and exclusion)
Type of patients (presence of baseline co-morbidity: AMI or chronic obstructive pulmonary disease)
Description of baseline criteria for severity of illness
Report of interventions (technical description of CPAP and NPPV methods)
Report of objective criteria for endotracheal intubation (adequate, inadequate or uncertain)
CPAP, continuous positive airway pressure ventilation; NPPV, non-invasive positive pressure ventilation.Critical Care    Vol 10 No 2    Winck et al.
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Figure 1
Flow chart of the study selection process Flow chart of the study selection process. ACPO, acute cardiogenic pulmonary edema; ARF = acute respiratory failure; CPAP, continuous positive 
airway pressure ventilation; ETI, endotracheal intubation; NPPV, non-invasive positive pressure ventilation; MT, medical therapy.Available online http://ccforum.com/content/10/2/R69
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Table 2
General characteristics and general quality criteria of randomized trials in acute cardiogenic pulmonary edema patients included in 
the study
Reference Country and 
Setting
Sample 
size
Interventions Outcomes 
analyzed
Randomization 
assignment 
concealmenta
Objective 
selection 
criteriab
Blindingc Standardization 
of co-
interventionsd
Intention-to-
treat analysise
Complete 
follow-up 
detailsf
Outcome 
definitiong
Rasanen et 
al. 1985 [62]
Finland: ED 
and ICU
40 SMT vs CPAP Meeting 
criteria for 
ETI during 3 
h follow-up; 
in-hospital 
mortality
Adequate Yes NR Yes Adequate Yes Adequate
Bersten et al. 
1991 [63]
Australia: 
ICU
39 SMT vs CPAP Meeting 
criteria for 
ETI during 
24 h follow-
up; in-
hospital 
mortality
Uncertain Yes No Yes Uncertain Yes Adequate
Lin et al. 
1995 [57]
Taiwan: ICU 100 SMT vs CPAP Meeting 
criteria for 
ETI during 6 
h follow-up; 
in-hospital 
mortality
Uncertain Yes NR Yes Adequate Yes Adequate
Takeda et al. 
1997 [11]
Japan: CU 30 SMT vs CPAP Meeting 
criteria for 
ETI during 
24 h follow-
up; in-
hospital 
mortality
Uncertain Yes NR Yes Adequate Yes Adequate
Takeda et al. 
1998 [12]
Japan: CU 22 SMT vs CPAP Meeting 
criteria for 
ETI during 
48 h follow-
up; in-
hospital 
mortality
Adequate Yes NR Yes Adequate Yes Adequate
Kelly et al. 
2002 [16]
Scotland, 
UK: ED and 
HDU
58 SMT vs CPAP Meeting 
criteria for 
treatment 
failure; in-
hospital 
mortality
Adequate Yes NR Yes Adequate Yes Inadequate
L'Her et al. 
2004 [22]
France: ED 89 SMT vs CPAP Meeting 
criteria for 
ETI or death 
during 48 h 
follow-up; in-
hospital 
mortality
Adequate Yes NR Yes Adequate Yes Adequate
Masip et al. 
2000 [13]
Spain: ED 
and ICU
37 SMT vs NPPV Meeting 
criteria for 
ETI during 
10 h follow-
up; in-
hospital 
mortality; 
AMI 
incidence
Adequate Yes No Yes Uncertain Yes Adequate
Levitt et al. 
2001 [14]
USA: ED 38 SMT vs NPPV ETI decided 
by attending 
physician 
during 24 h 
follow-up; in-
hospital 
mortality; 
AMI 
incidence.
Adequate Yes NR Uncertain Uncertain Yes UncertainCritical Care    Vol 10 No 2    Winck et al.
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Nava et al. 
2003 [19]
Italy: ED 130 SMT vs NPPV Meeting 
criteria for 
ETI during 
24 h follow-
up; in-
hospital 
mortality; 
AMI 
incidence
Adequate Yes NR Yes Adequate Yes Adequate
Mehta et al. 
1997 [25]
USA: ED 27 CPAP vs 
NPPV
ETI decided 
by attending 
physician 
during 24 h 
follow-up; in-
hospital 
mortality; 
AMI 
incidence
Adequate Yes Yesh Yes Adequate Yes Uncertain
Martin-
Bermudez et 
al. 2002 [17]
Spain: ED 80 CPAP vs 
NPPV
Meeting 
criteria for 
ETI during 
24 h follow-
up; in-
hospital 
mortality; 
AMI 
incidence
Uncertain Yes NR Uncertain Adequate Yes Uncertain
Bellone et al. 
2004 [20]
Italy: ED 46 CPAP vs 
NPPV
Meeting 
criteria for 
ETI during 
36 h follow-
up; in-
hospital 
mortality; 
AMI 
incidence
Adequate Yes No Yes Adequate Yes Adequate
Bellone et al. 
2005 [24]
Italy: ED 36 CPAP vs 
NPPV
Meeting 
criteria for 
ETI during 
36 h follow-
up; in-
hospital 
mortality
Adequate Yes No Yes Adequate Yes Adequate
Park et al. 
2001 [15]
Brazil: ED 26 SMT vs CPAP 
vs NPPV
ETI decided 
by attending 
physician 
during 1 h 
follow-up; in-
hospital 
mortality; 
AMI 
incidence
Uncertain Yes NR Yes Uncertain Yes Inadequate
Park et al. 
2004 [23]
Brazil: ED 80 SMT vs CPAP 
vs NPPV
ETI decided 
by attending 
physician 
during 24 h 
follow-up; in-
hospital 
mortality; 
AMI 
incidence
Adequate Yes NR Yes Adequate Yes Uncertain
Crane et al. 
2004 [21]
UK: ED 60 SMT vs CPAP 
vs NPPV
Meeting 
criteria for 
ETI during 2 
h follow-up; 
in-hospital 
mortality; 
AMI 
incidence
Adequate Yes No Yes Adequate Yes Adequate
Table 2 (Continued)
General characteristics and general quality criteria of randomized trials in acute cardiogenic pulmonary edema patients included in 
the studyAvailable online http://ccforum.com/content/10/2/R69
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aClassified as: adequate, inadequate or uncertain. bClassified as: yes, if inclusion and exclusion criteria for participants are adequately reported; no, 
if selection criteria are not reported. cClassified as: yes, for articles that implemented blinding at any level; no, for articles reporting not being able to 
implement blinding of interventions at any level; not reported (NR), for articles that do not make any mention to blinding. dClassified as: yes, if there 
was an attempt to standardize treatment and care besides the assigned interventions; no, if no attempt to standardize was applied; uncertain, if it 
was not clearly reported. eClassified as: adequate; inadequate; uncertain. fClassified as: yes; no; not reported (NR). gClassified as: adequate if 
objective criteria for endotracheal intubation were defined; inadequate if the criteria were not defined; and uncertain if criteria application was 
unclear (for example, depending on attending physician). hIn this study physicians, nurses and patients were blinded by covering the control panel 
on the device. AMI, acute myocardial infarction; CPAP, continuous positive airway pressure; CU, coronary unit; ED, emergency department; ETI, 
endotracheal intubation; HDU, high dependency unit; ICU, intensive care unit; NPPV, non-invasive pressure ventilation; SMT, standard medical 
therapy.
Figure 2
Results and pooled analysis of absolute risk differences (RDs) for the outcomes (a) need for endotracheal intubation, (b) mortality and (c) acute  myocardial infarction in trials comparing continuous positive airway pressure ventilation (CPAP) versus medical therapy in acute cardiogenic pulmo- nary edema patients Results and pooled analysis of absolute risk differences (RDs) for the outcomes (a) need for endotracheal intubation, (b) mortality and (c) acute 
myocardial infarction in trials comparing continuous positive airway pressure ventilation (CPAP) versus medical therapy in acute cardiogenic pulmo-
nary edema patients.
Table 2 (Continued)
General characteristics and general quality criteria of randomized trials in acute cardiogenic pulmonary edema patients included in 
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Table 3
Specific quality criteria of included randomized trials
Reference Inclusion criteriaa Exclusion criteria Baseline co-
morbidity: AMI, 
COPDb
Intervention in 
experimental group 
CPAP
Intervention in 
experimental group 
NPPV
Intervention in 
control group SMTc
Objective criteria for 
endotracheal 
intubationd
Rasanen et al. 
1985 [62]
Clinical criteria of 
APE; RR >25/min; 
PaO2/FiO2 <200
COPD; unresponsive; 
unable to maintain 
patent airway; lung 
infection; pulmonary 
embolism
AMI: control 10/20; 
CPAP 9/20 COPD: 
none
CPAP 10 cmH2O 
face mask plus 
medical therapy
- SMT Adequate Criteria for 
ETI: PaO2<50 
mmHg; PaCO2 > 55 
mmHg; RR >35/min; 
unresponsiveness; 
airway obstruction
Bersten et al. 
1991 [63]
Clinical criteria of 
APE; PaO2 < 70 
mmHg; PaCO2 > 45 
mmHg when O2 8 l/
min
AMI and shock; SBP 
<90 mmHg; stenotic 
VHD; COPD and 
CO2 retention
AMI: control 4/20; 
CPAP 3/19 COPD: 
none
CPAP 10 cmH2O 
face mask plus 
medical therapy
- SMT Adequate Criteria for 
ETI: clinical 
deterioration; PaO2 < 
70 mmHg with O2 
100%; PaCO2 > 55 
mmHg
Lin et al. 1995 
[57]
Clinical criteria of 
APE; PaO2/FIO2 = 
200–400; P [A-a] O2 
> 250 mmHg
Unresponsive; unable 
to maintain patent 
airway; shock; septal 
rupture; stenotic 
VHD; COPD and 
CO2 retention
AMI: control 11/50; 
CPAP 10/50 
COPD: none
CPAP face mask 
titrated up – 2.5, 5, 
7.5, 10 and 12.5 
cmH2O plus 
medical therapy
-S M T  ( p l u s  
dopamine)
Adequate Criteria for 
ETI: cardiac 
resuscitation or 
clinical deterioration 
and two of the 
following – PaCO2 > 
55 mmHg, PaO2/
FiO2 < 200 mmHg, 
RR >35
Takeda et al. 
1997 [11]
Clinical criteria of 
APE; respiratory 
distress; PaO2 < 80 
mmHg while 
receiving ≥50% O2
Not reported AMI: CPAP 5/15; 
Control 6/15 
COPD: none
CPAP 4–10 
cmH2O nasal mask 
plus medical 
therapy
-S M T  ( p l u s  
dopamine, 
dobutamine, 
norepinephrine and 
digitalis)
Adequate Criteria for 
ETI: clinical 
deterioration and 
PaO2/FiO2 <100 
mmHg (with FiO2 
≥70%), PaCO2 >55 
mmHg
Takeda et al. 
1998 [12]
Clinical criteria of 
APE; PaO2 < 80 
mmHg
Shock; septal or 
ventricular rupture
All 22 patients with 
AMI admitted to the 
coronary unit
CPAP 4–10 
cmH2O nasal mask 
plus medical 
therapy
-S M T  ( p l u s  
dopamine, 
dobutamine, 
norepinephrine)
Adequate Criteria for 
ETI: clinical 
deterioration and 
PaO2/FiO2 <100 
mmHg (with FiO2 
≥70%) PaCO2 >55 
mmHg
Kelly et al. 2002 
[16]
Clinical criteria of 
APE; RR > 20/min
Pneumonia; 
pneumothorax; pre-
hospital treatment 
with interventions 
other than oxygen, 
diuretics or opiates
AMI: not reported 
COPD: not reported
CPAP 7.5 cmH2O 
face mask plus 
medical therapy
- SMT Inadequate Criteria 
for treatment failure: 
need for intubation 
(no defined criteria), 
hypoxemia or 
hypercapnia and 
respiratory distress
L'Her, et al. 
2004 [22]
Clinical criteria of 
APE Age >75 years; 
PaO2/FiO2 <300 
mmHg, RR >25/min
GCS <7; Sat O2 
<85%; SBP <90 
mmHg); chronic 
respiratory 
insufficiency
AMI: not reported 
(acute ischemic 
heart disease: 
control 6/46; CPAP 
7/43) COPD: none
Face mask CPAP 
7.5 cmH2O plus 
medical therapy
- SMT Adequate Serious 
complications 
considered as death 
or need for ETI within 
48 h. Criteria for ETI: 
cardiac or respiratory 
arrest; SBP <80 
mmHg; progressive 
hypoxemia (Sat O2 
<92%); coma or 
seizures; agitation
Masip et al. 
2000 [13]
Clinical criteria of 
APE
AMI; pneumonia; 
SBP <90 mmHg; 
CRF; immediate 
intubation; 
neurological 
deterioration
AMI: control 6/18; 
NPPV 5/19 COPD: 
control 7/18; NPPV 
3/19
- NPPV face mask, 
PEEP 5 cmH2O, 
plus medical 
therapy PSV 15.2 ± 
2.4 cmH2O
SMT Adequate Criteria for 
ETI: cardiac or 
respiratory arrest, 
hypoxemia (Sat O2 
<80%) and muscles 
fatigue
Levitt et al. 
2001 [14]
Clinical criteria of 
APE; RR >30/min
Immediate need for 
intubation; radiograph 
not compatible with 
APE
AMI: none COPD: 
not reported
- NPPV S/T mode, 
face or nasal mask, 
initial IPAP of 8 and 
EPAP of 3 cmH2O, 
pressure support of 
5 cmH2O plus 
medical therapy 
PSV 5.0 cmH2O
SMT Uncertain Decision 
by attending 
physician based on 
the following criteria: 
respiratory distress, 
deterioration in 
mental status or vital 
signs, PaO2 <60 
mmHg, PaCO2 >50 
mmHgAvailable online http://ccforum.com/content/10/2/R69
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Nava et al. 2003 
[19]
Clinical criteria of 
APE; PaO2/FiO2 < 
250; RR >30/min
AMI needing 
thrombolysis; 
immediate need for 
intubation; Kelly score 
>3; shock; 
arrhythmias; 
SpO2<80%; severe 
CRF; pneumothorax
AMI: control 11/65; 
NPPV 11/65 
COPD: control 26/
65; NPPV 27/65
- NPPV S mode face 
mask IPAP 14.5 ± 
21.1 cmH2O, 
EPAP: 6.1 ± 3.2 
cmH2O plus 
medical therapy 
PSV 8.4 cmH2O
SMT Adequate Sat O2 
<85% with FiO2 
100%, cardiac or 
respiratory arrest, 
inability to tolerate 
mask, PaCO2 >50 
mmHg, signs of 
pump exhaustion, 
SBP <90 mmHg, 
AMI, massive GI 
bleeding
Mehta et al. 
1997 [25]
Clinical criteria of 
APE; RR >30/min; 
tachycardia >100 
bpm; without 
pulmonary aspiration 
or infection
Immediate need for 
intubation; respiratory 
or cardiac arrest; 
arrhythmias; SBP 
<90 mmHg; 
unresponsive; 
agitated; condition 
precluding use of 
face mask
AMI: CPAP 1/13; 
NPPV 1/14 Chest 
pain: CPAP 4/13; 
NPPV 10/14; 
COPD: not reported
CPAP 10 cmH2O 
nose/face mask 
plus medical 
therapy
NPPV S/T mode, 
nasal/face mask, 
IPAP 15 cmH2O, 
EPAP 5 cmH2O, 
plus medical 
therapy PSV 10.0 
cmH2O
- Uncertain Decision 
by attending 
physician based on 
the following criteria: 
severe respiratory 
distress, inability to 
tolerate mask, 
unstable vital signs, 
PaO2 <60 mmHg or 
increase PaCO2 >5 
mmHg
Martin-
Bermudez, et al. 
2002 [17]
Clinical criteria of 
APE; RR >25/min; 
Sat O2 <90%
Not reported AMI: not reported 
COPD: not reported
Face mask CPAP 
plus medical 
therapy
Face mask NPPV 
plus medical 
therapy PSV 
uncertain
- Uncertain
Bellone et al. 
2004 [20]
Clinical criteria of 
APE; Sat O2 <90%; 
RR >30/min
Acute coronary 
syndrome; immediate 
need for intubation; 
respiratory or cardiac 
arrest; SBP <90 
mmHg; unresponsive, 
agitated or unable to 
cooperate; condition 
precluding use of 
face mask
AMI: none COPD: 
CPAP 8/22; NPPV 
6/24
Face mask CPAP 
10 cmH2O plus 
medical therapy
Face mask NPPV 
initially IPAP 15 
cmH2O and EPAP 
5 cmH2O, with 
adjustments as 
needed to obtain 
tidal volume >400 
ml plus medical 
therapy PSV 10.0 
cmH2O
-A d e q u a t e  
Respiratory arrest; 
loss of 
consciousness; 
agitation; heart rate 
<50/min, SBP <70 
mmHg
Bellone et al. 
2005 [24]
Clinical criteria of 
APE; PaCO2 > 45 
mmHg; Sat O2 
<90%; RR >30/min
COPD; PaCO2 <45 
mmHg; immediate 
need for intubation; 
respiratory or cardiac 
arrest; SBP <90 
mmHg; CRF; 
agitated; condition 
precluding use of 
face mask; enrolled in 
other study
AMI: CPAP 0/18; 
NPPV 2/18 COPD: 
none
Face mask CPAP 
10 cmH2O plus 
medical therapy
Face mask NPPV 
initially IPAP 15 
cmH2O, EPAP 5 
cmH2O, 
adjustments to 
obtain tidal volume 
>400 ml plus 
medical therapy 
PSV 10.0 cmH2O
-A d e q u a t e  
Respiratory arrest; 
loss of 
consciousness; 
agitation; heart rate 
<50/min, SBP <70 
mmHg
Park et al. 2001 
[15]
Clinical criteria of 
APE; RR >25/min
COPD; SBP <90 
mmHg; arrhythmias; 
bradypnea; 
unresponsive, 
agitated or unable to 
cooperate; vomiting; 
digestive 
hemorrhage; facial 
deformities
AMI: control 2/10; 
CPAP 1/9; NPPV 1/
7 COPD: none
Face mask CPAP 
mean 7.5 cmH2O, 
initially 5, increased 
by 2.5, maximum 
12.5 cmH2O, plus 
medical therapy
NPPV S/T mode 
nasal mask, IPAP 
12 cmH2O, EPAP 4 
cmH2O, plus 
medical therapy 
PSV 8.0 cmH2O
SMT Inadequate Decision 
made by the 
attending physician 
based on clinical and 
laboratory findings
Park et al. 2004 
[23]
Clinical criteria of 
APE; RR >25/min
AMI; COPD; 
pulmonary embolism; 
pneumonia; 
pneumothorax; SBP 
<90 mmHg; vomiting
AMI: control 3/26; 
CPAP 1/27; NPPV 
1/27 COPD: none
Face mask CPAP 
initially 11 ± 2 
cmH2O plus 
medical therapy
Face mask NPPV, 
IPAP 17 ± 2 
cmH2O, EPAP 11 ± 
2 cmH2O, plus 
medical therapy 
PSV 6.0 cmH2O
SMT Uncertain Decision 
made by the 
attending physician 
based on the 
following criteria: 
GCS <13, 
respiratory distress, 
PaO2 <60 mmHg, 
Sat O2 <90%, 
increase PaCO2 >5 
mmHg
Crane et al. 
2004 [21]
Clinical criteria of 
APE; RR >23/min; 
pH <7.35
SBP <90 mmHg; 
temperature >38°C; 
AMI with 
thrombolysis; dialysis 
for CRF; impaired 
consciousness; 
dementia
AMI: none COPD: 
control 6/20; CPAP 
3/20; NPPV 7/20
Face mask CPAP 
10 cmH O plus 
medical therapy
Face mask NPPV 
IPAP 15 cmH2O, 
EPAP 5 cmH2O 
plus medical 
therapy PSV 10.0 
cmH2O
SMT Adequate RR >40 or 
<10 and reduced 
consciousness; 
falling pH (<7.2)
Table 3 (Continued)
Specific quality criteria of included randomized trialsCritical Care    Vol 10 No 2    Winck et al.
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from 2000 to 2005, and contacted authors and experts work-
ing in this field.
Study quality assessment and data abstraction
In the first phase of selection, the titles and abstracts of the
retrieved studies were screened for relevance by two review-
ers. In the second phase, two reviewers (ALF and WJC) inde-
pendently analyzed the full-papers of articles identified as
potentially relevant. Selection criteria were applied, exclusions
were decided and disagreements settled by consensus. Data
abstraction for quality assessment and pooled analysis was
performed independently using a previously specified stand-
ardized form. Quality assessment considered two types of
study quality criteria, general and specific.
The general quality criteria included methodological and
reporting characteristics of RCTs generally accepted as
appropriate to evaluate this type of study (Table 1). The spe-
cific quality criteria included characteristics specifically rele-
vant to RCTs studying ACPE patients and the effect of non-
invasive ventilation (Table 1).
aClinical criteria of APE: existence of dyspnea of sudden onset, bilateral pulmonary infiltrates on chest radiograph and a compatible physical 
examination (bilateral crackles on pulmonary auscultation, elevated jugular venous pressure, third heart sound on cardiac auscultation). bData on 
baseline frequency of acute myocardial infarction (AMI) and chronic obstructive pulmonary disease (COPD) are presented as number of patients 
with co-morbidity/total number of patients in the assigned group. cStandard medical therapy was defined as: O2 by face mask, nitro-glycerin, 
nitroprusside, furosemide and morphine. Other interventions described in managing these patients will be specifically indicated. dClassified as: 
adequate if objective criteria for endotracheal intubation were defined; inadequate if the criteria were not defined; and uncertain if criteria application 
was unclear (for example, depending on attending physician). APE, acute pulmonary edema; bpm, beats per minute; CPAP, continuous positive 
airway pressure; CRF, chronic renal failure; DBP, diastolic blood pressure; EPAP, expiratory positive airway pressure; ETI, endotracheal intubation; 
FiO2, O2 inspired fraction; GI, Gastrointestinal; GCS, Glasgow coma scale; IPAP, inspiratory positive airway pressure; NPPV, non-invasive pressure 
ventilation; P [A-a], arterial/alveolar partial pressure differential; PaCO2, CO2 partial pressure; PaO2, O2 partial pressure; PEEP, positive end 
expiratory pressure; PSV, pressure support ventilation; RR, respiratory rate; Sat O2, O2 saturation; SBP, systolic blood pressure; S mode, 
spontaneous mode; SMT, standard medical therapy; SpO2, pulse oximetry oxygen saturation; S/T mode, spontaneous/timed mode; VHD, valvular 
heart disease.
Figure 3
Results and pooled analysis of absolute risk differences (RDs) for the outcomes (a) need for endotracheal intubation, (b) mortality and (c) acute  myocardial infarction in trials comparing non-invasive positive pressure ventilation (NPPV) versus medical therapy in acute cardiogenic pulmonary  edema patients Results and pooled analysis of absolute risk differences (RDs) for the outcomes (a) need for endotracheal intubation, (b) mortality and (c) acute 
myocardial infarction in trials comparing non-invasive positive pressure ventilation (NPPV) versus medical therapy in acute cardiogenic pulmonary 
edema patients.
Table 3 (Continued)
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Statistical analysis
For the pooled assessment of treatment effects in the three
comparisons (CPAP versus SMT, NPPV versus SMT and
CPAP versus NPPV) and the three outcome variables (need
for ETI, mortality and AMI risk) in this review, we used the Man-
tel-Haenszel method for fixed effects estimation and the Der-
Simonian and Laird method for random effects estimation.
One problem that could have arisen in the pooled analysis is
that of patient overlap because of the inclusion of studies with
three arms (CPAP, NPPV and SMT)[15,21,23]. To overcome
this problem, among other previously stated reasons, we sep-
arately considered the three comparisons CPAP versus SMT,
NPPV versus SMT and CPAP versus NPPV.
We used risk difference (absolute risk reduction) as the scale
for measuring efficacy and side effects because clinicians find
it a more intuitive and interpretable metric as it measures the
absolute difference between outcome risks in intervention and
control groups, rather than odds ratios or relative risks, which
many clinicians and patients find hard to understand [34,35].
Heterogeneity of treatment effects was assessed by graphical
inspection of forest plots and formally using the Q statistic (at
a p value ≤ 0.1) and I2 statistic for estimating inconsistency
among study results. The random effects model for pooling
effects was preferred and always used if heterogeneity of
treatment effects was present. Subgroup and sensitivity anal-
ysis were performed following a predefined protocol and con-
sidering the hypothesis previously presented.
Potential publication bias was assessed by visual analysis of
the funnel plots, which allows evaluation of publication bias by
presenting the study's risk difference plotted as a function of
its standard error, and then formally checked by the rank cor-
relation test of Begg [36].
The data processing and statistical analysis were performed
using the Cochrane Collaboration's Review Manager Soft-
ware version 4.2 [37] and RevMan Analyses software version
1.0 [38].
Figure 4
Results and pooled analysis of absolute risk differences (RDs) for the outcomes (a) need for endotracheal intubation, (b) mortality and (c) acute  myocardial infarction in trials comparing of continuous positive airway pressure ventilation (CPAP) versus non-invasive positive pressure ventilation  (NPPV) in acute cardiogenic pulmonary edema patients patients Results and pooled analysis of absolute risk differences (RDs) for the outcomes (a) need for endotracheal intubation, (b) mortality and (c) acute 
myocardial infarction in trials comparing of continuous positive airway pressure ventilation (CPAP) versus non-invasive positive pressure ventilation 
(NPPV) in acute cardiogenic pulmonary edema patients patients.Critical Care    Vol 10 No 2    Winck et al.
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Results
Search and study selection
A total of 790 articles were identified using the search strategy
and sources listed. After screening titles and abstracts for rel-
evance, 744 articles were excluded (the reasons for exclusion
are presented in Figure 1). The remaining 46 articles were
retrieved for more detailed full paper evaluation and 22 were
excluded [18,39-51] (Figure 1). Eight other articles reporting
randomized controlled trials in ACPE patients were excluded,
for the following reasons: two because different interventions
were studied [52,53]; one because it was a randomized cross-
over trial focusing on physiological outcome variables [54];
two because of probable patient overlap [55,56] with the
included studies by Crane and colleagues [21] and Lin and
colleagues [57]; one because its abstract and full paper were
published in Chinese [58]; one (by Sharon and colleagues
[59]) because it was performed in a pre-hospital setting and
had a different intervention in the control group – SMT plus
high dose IV isossorbide-dinitrate – and has been frequently
criticized for its methodological problems [60]; and one con-
ference abstract by Liesching and colleagues reporting an
RCT comparing NPPV versus CPAP was withdrawn because
it was not possible to obtain the minimum information on study
design, patients, interventions and outcomes [61].
Unlike the other meta-analysis previously published [27], we
did not excluded the article by Takeda and colleagues [12]
because there is no evidence of patient overlap with the other
study by the same authors [11]. Patient inclusions in the two
articles have different time frames and settings [11,12].
The final study cohort consisted of 17 studies: seven compar-
ing CPAP with SMT [11,12,16,22,57,62,63], three comparing
NPPV with SMT [13,14,19], four comparing CPAP directly
with NPPV [17,20,24,25] and three studies each with three
arms comparing CPAP, NPPV and SMT [15,21,23] (Table 2).
Methodological quality of included studies
Study quality assessment considered two types of criteria:
general and specific. The general quality criteria are presented
in Table 2. The studies had generally small sample sizes
(median, 40 patients; range, 22 to 130); the total number of
Figure 5
Results and pooled analysis of absolute risk differences (RDs) for the outcomes (a) need for endotracheal intubation, (b) mortality and (c) acute  myocardial infarction in trials comparing of continuous positive airway pressure ventilation (CPAP) versus non-invasive positive pressure ventilation  (NPPV) in acute cardiogenic pulmonary edema patients patients Results and pooled analysis of absolute risk differences (RDs) for the outcomes (a) need for endotracheal intubation, (b) mortality and (c) acute 
myocardial infarction in trials comparing of continuous positive airway pressure ventilation (CPAP) versus non-invasive positive pressure ventilation 
(NPPV) in acute cardiogenic pulmonary edema patients patients. Subgroup analysis with stratification by baseline PaCO2 level.Available online http://ccforum.com/content/10/2/R69
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patients included was 938. Most of them had adequate rand-
omization concealment and adequate selection criteria. Four
out of 17 did not report an intention-to-treat analysis. Only one
study blinded physicians, nurses and patients to the interven-
tion by covering the control panel of the ventilator. Almost
none of the studies reported or commented on blinding strat-
egies. Most of them reported on strategies for standardization
of co-interventions and had complete follow-up details for all
participants. Six out of 17 studies had inadequate or unclear
outcome definitions.
The specific quality criteria are presented in Table 3. There
were several different definitions of ACPE (see Table 3), but
most of them included the basic criteria considered in our def-
inition (existence of dyspnea of sudden onset, increased res-
piratory rate, a compatible physical examination, bilateral
crackles on pulmonary auscultation, elevated jugular venous
pressure, third heart sound on cardiac auscultation, bilateral
pulmonary infiltrates on chest radiograph plus significant
hypoxemia). Inclusion and exclusion criteria had some variabil-
ity (Table 3), with some studies including much selected
groups of patients. Baseline co-morbidities differed between
studies and in some studies the presence of chronic obstruc-
tive pulmonary disease (COPD) or AMI was considered as
exclusion criteria (Table 3). The frequency of AMI at baseline,
for each study, is presented in Table 3. Major differences were
found among studies regarding the methods of implementa-
tion and technical characteristics of the ventilation devices
(Table 3) and regarding the definition and adequacy of criteria
for ETI (Table 3).
The analysis of safety issues will mainly focus on comparisons
of AMI risk among interventions. Some other adverse events of
non-invasive ventilation were reported sporadically by authors
(facial erythema, nasal skin necrosis, vomiting, gastric disten-
sion, pulmonary aspiration, barotrauma and asphyxia), but
were always described as rare events.
Continuous positive airway pressure ventilation versus 
standard medical therapy
Results of studies comparing CPAP therapy with SMT are pre-
sented in Figure 2. In the random effects pooled analysis,
CPAP therapy showed a statistically significant 22% risk
reduction in need for ETI (95% confidence interval (CI), -34%
to -10%; p = 0.0004) and a 13% risk reduction for mortality
(95%CI, -22% to -5%; p = 0.0003). Significant heterogeneity
was found in the pooled analysis of need for ETI and borderline
significant heterogeneity was found for mortality (Cochran's Q
chi-square test, p = 0.0004; I2 = 70.1% for intubation and
Cochran's Q chi-square test, p = 0.060; I2 = 44.1% for mor-
tality). Nevertheless, all studies but one found a reduction of
risk in the CPAP group. Heterogeneity is in part related to the
extreme findings of 55% risk reduction for both ETI and mor-
tality in the study by Takeda and colleagues [12].
Only three studies included data on myocardial infarction and
the random effects pooled analysis showed no difference in
AMI risk between the CPAP and SMT groups (Risk Difference
– RD, -1%; 95%CI, -13% to 11%; p = 0.910) and non-signif-
icant heterogeneity (Cochran's Q chi-square test, p = 0.22; I2
= 33.2%).
Figure 6
Funnel plots with effect measures (risk difference (RD)) as a function of  its standard error (SE) for the outcome endotracheal intubation in trials  comparing (a) continuous positive airway pressure ventilation (CPAP)  versus medical therapy; (b) non-invasive positive pressure ventilation  (NPPV) versus medical therapy and CPAP versus NPPV Funnel plots with effect measures (risk difference (RD)) as a function of 
its standard error (SE) for the outcome endotracheal intubation in trials 
comparing (a) continuous positive airway pressure ventilation (CPAP) 
versus medical therapy; (b) non-invasive positive pressure ventilation 
(NPPV) versus medical therapy and CPAP versus NPPV.Critical Care    Vol 10 No 2    Winck et al.
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Non-invasive positive pressure ventilation versus 
standard medical therapy
Results of the studies comparing NPPV with SMT are pre-
sented in Figure 3. The random effects pooled analysis
showed a statistically significant 18% risk reduction in need
for ETI (95%CI, -32% to -4%; p = 0.010) and a non-significant
7% risk reduction for mortality (95%CI, -14% to 0%; p =
0.060) favoring the NPPV group. Significant heterogeneity
was found in the pooled analysis of need for ETI (Cochran's Q
chi-square test, p = 0.02; I2 = 62.9%), but again, all studies
but one showed risk reduction for the NPPV group.
Random effects pooled analysis of risk differences for AMI
showed a small but non-significant risk increase for the NPPV
group (RD, 1%; 95%CI, -4% to 5%; p = 0.720).
To test the clinical hypothesis about an advantage of NPPV
over SMT when using higher levels of pressure support venti-
lation [26], we performed a predefined subgroup analysis (For-
est plots not presented but available on request) with
stratification based on the level of pressure support ventilation
(Pressure Support Ventilation – PSV ≥ 10.0 cmH2O versus
PSV < 10.0 cmH2O; Table 3). In the subgroup of studies with
higher levels of pressure support ventilation [13,21], a random
effects pooled analysis showed a statistically non-significant
risk reduction in need for ETI (RD, -13%; 95%CI -44% to
19%; p = 0.430; Cochran's Q chi-square test for heterogene-
ity, p = 0.020) and mortality (RD, -9%; 95%CI -24% to 5%; p
= 0.190; Cochran's Q chi-square test for heterogeneity, p =
0.670) favoring the NPPV group. In the subgroup of studies
with lower levels of pressure support ventilation
[14,15,19,23], the random effects pooled analysis showed a
statistically significant risk reduction in need for ETI (RD, -
22%; 95%CI -40% to -3%; p  = 0.020; Cochran's Q chi-
square test for heterogeneity, p = 0.060) and a non-significant
risk reduction for mortality (RD, -6%; 95%CI -14% to 2%; p =
0.160; Cochran's Q chi-square test for heterogeneity, p =
0.690) favoring the NPPV group.
Continuous positive airway pressure ventilation versus 
non-invasive positive pressure ventilation
Results from studies directly comparing CPAP with NPPV are
presented in Figure 4. The random effects pooled analysis
showed a statistically non-significant need for ETI risk reduc-
tion (RD, 3%; 95%CI -4% to 9%; p = 0.041) and mortality
reduction (RD, 2%; 95%CI -6% to 10%; p = 0.640) in the
NPPV group. No evidence of significant heterogeneity in need
for ETI was found (Cochran's Q chi-square test, p = 0.340; I2
= 11.5%). Heterogeneity with borderline significance was
found for mortality (Cochran's Q chi-square test, p = 0.100; I2
= 44.4%). A fixed effects pooled analysis, which could be con-
sidered appropriate in this case due to the absence of hetero-
geneity, obtained similar non-significant results (RD, 4%;
95%CI -2% to 10% and RD, 2%; 95%CI -5% to 8% for ETI
and mortality, respectively).
Random effects pooled analysis of risk differences for AMI
showed a non-significant risk reduction in the CPAP group
(RD, -5%; 95%CI, -18% to 8%; p = 0.430).
To explore the hypothesis proposed by some clinicians on the
advantage of NPPV over CPAP in hypercapnic patients [19],
we analyzed the impact of patients' baseline hypercapnia in
the comparison between CPAP and NPPV. A subgroup anal-
ysis was performed (Figure 5) with stratification based on
mean baseline level of arterial carbon dioxide pressure,
(PaCO2 <50 mmHg versus PaCO2 ≥ 50 mmHg). In the group
of studies with more hypercapnic patients at baseline, the ran-
dom effects pooled analysis showed a statistically non-signifi-
cant risk reduction in need for ETI (RD, 2%; 95%CI -5% to
9%; p = 0.560) and mortality (RD, 2%; 95%CI -9% to 13%;
p = 0.690) favoring the NPPV group. In the group of studies
with less hypercapnic patients at baseline, the random effects
pooled analysis showed a statistically non-significant risk
reduction in need for ETI (RD, 13%; 95%CI -20% to 46%; p
= 0.430) and a non-significant risk increase for mortality (RD,
-1%; 95%CI -12% to 10%; p = 0.820) for the NPPV group.
Publication bias
Funnel plots are presented in Figure 6. Although separate
analyses for all outcomes and comparisons were performed,
we only present here the analysis of potential publication bias
for the need for ETI, because results regarding other out-
comes are very similar.
For the comparison of CPAP versus SMT, the funnel plot is
approximately symmetrical, but larger studies (more precise
measures of effect) tend to have smaller effects and smaller
studies (less precise measures of effect) tend to have larger
effects. The rank correlation test of Begg gives a non-signifi-
cant result (p = 0.325), so the absence of publication bias
cannot be rejected. For the comparison of NPPV versus SMT
the funnel plot is asymmetrical and seems to indicate a lack of
small studies with small effects. The rank correlation test of
Begg gives a non-significant result (p = 0.251). For the com-
parison of CPAP versus NPPV the funnel plot is asymmetrical
and indicates a lack of small studies with effects favoring
CPAP therapy. For this comparison, there seems to be some
evidence of a publication bias, favoring the publication of stud-
ies with positive results for NPPV therapy. Nonetheless, the
rank correlation test of Begg gives, once again, a non-signifi-
cant result (p = 0.129).
Discussion
ACPE is a rather common condition and may require mechan-
ical ventilation [64], leading to high in-hospital mortality. The
use of non-invasive ventilation to treat ACPE was first
described by Poulton and colleagues [65] more than 60 years
ago, and seven years ago the first meta-analysis appeared,
showing the efficacy of CPAP in the treatment of ACPE [10].
Since then, several RCTs comparing the use of CPAP andAvailable online http://ccforum.com/content/10/2/R69
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NPPV with SMT or with each other have been published, and
the role of non-invasive ventilation, and specially CPAP, in
ACPE patients is becoming more clearly defined.
The present meta-analysis focused on important, unresolved
clinical questions about the efficacy and safety of these tech-
niques that could be delaying their uptake in most centers.
First, the meta-analysis shows that, in patients with ACPE,
CPAP and NPPV, both significantly decrease need for ETI risk,
and CPAP alone significantly reduces mortality when com-
pared to SMT. Both NPPV and CPAP appear to be equivalent
in reducing need for ETI and mortality. NPPV does not yet
show a significant reduction in mortality, probably due to the
low power related to the limited number of patients in the stud-
ies analyzed.
To put this evidence of clinical efficacy into context, it is also
important to take into account the costs and difficulties
involved in implementing non-invasive ventilation in clinical
practice and the logistic differences between using the two
non-invasive ventilation techniques. It is clear that CPAP is
more easily implemented in clinical practice and that it carries
smaller associated costs [53]. In fact, the cost-effectiveness of
CPAP has already been demonstrated [66].
Second, our analysis of the safety of these methods showed
that, although some caution is still advised, there is no evi-
dence of increased risk of AMI with either of these techniques
and the other adverse events described with these techniques
are very rare. Although one study [25] found a higher inci-
dence of AMI with NPPV, subsequent research has not con-
firmed this finding [13,19-21,23]. In the present meta-analysis,
there was no significant difference in the risk of AMI between
CPAP and NPPV when compared to SMT. Careful and fre-
quent monitoring of patients with ACPE is mandatory, espe-
cially in the presence of AMI, but there is no evidence from
these trials to contraindicate the use of NPPV.
Third, in a subgroup analysis of studies including patients with
mean baseline PaCO2 levels below and above 50 mmHg,
NPPV showed only a small trend towards decreased need for
ETI and mortality, so the suggested superiority of NPPV in
hypercapnic ACPE patients due to respiratory muscle unload-
ing [19] was not confirmed. Although a number of studies in
our meta-analysis included patients with ACPE and coexisting
COPD [13,19-21], who one would expect to benefit the most
from NPPV [67], studies including hypercapnic ACPE patients
without COPD also showed significant improvement in
PaCO2 with CPAP [24].
Fourth, in a subgroup analysis we found no evidence support-
ing the clinical hypothesis about the advantage of NPPV over
SMT when using higher levels of pressure support ventilation
[26,13,21].
Although our conclusions appear robust and well supported
by the evidence, this meta-analysis has some limitations that
should be pointed out. We found important clinical differences
among the studies included in the analysis. The patients
selected may not be completely comparable from study to
study. Specifically, we found relevant differences relating to
the etiology of ACPE. The mortality rate in the control groups
had a wide range (from 0% [15] to 64% [12]), indicating large
differences in severity of illness between studies. In addition,
the rates of AMI on admission, one of the most important pre-
dictors of mortality [4,64,68] varied from 0% in Bellone and
colleagues [20] to 100% in Takeda and colleagues' study
[12].
Some of the studies included had moderate methodological
limitations. When analyzing the comparison between NPPV
and SMT, some concern may be raised about study recruit-
ment and randomization procedures. In fact, one study had
significantly more patients with a history of AMI, COPD and
diabetes mellitus and patients with higher baseline PaCO2 lev-
els randomized to the control group [13]. Studies comparing
CPAP with NPPV also had problems with baseline differences
between groups. For instance, in Park and colleagues' study
[15], patients treated with CPAP were more severely ill than
those treated with NPPV, and in the study by Crane and col-
leagues [21], the NPPV group had significantly more co-mor-
bidities, lower PaCO2 and a trend toward higher median peak
creatine kinase (CK) levels. These differences could poten-
tially account for the advantage of NPPV in reducing ETI in
Park and colleagues' study [15] and for the advantage of
CPAP in reducing mortality in Crane and colleagues' study
[21].
Important heterogeneity was also found in relation with out-
come definitions. The criteria and time frame used in the defi-
nition of patients needing ETI was very different from study to
study. Moreover, some studies considered the need for intuba-
tion as the outcome whereas others considered actual intuba-
tion. The creation of consensus guidelines for outcome
definitions for this type of study would be very useful to pro-
mote further rigorous research and would support future sys-
tematic reviewers.
Differences were also found in the technical specifications of
the ventilation devices studied. Although face mask was the
main interface used, in some studies [11,12,14,25] a nasal
mask or a combination of the two were applied. Duration of
non-invasive ventilation and the type of ventilator may have
also influenced outcomes, and this was not examined in this
review. Some different kinds of interfaces and ventilatory
modes have produced better patient comfort [69,70], but they
do not seem to have a major impact on survival or other out-
comes. The differences relating to ventilators and interfaces
among studies included in this meta-analysis do not seem to
account for the differences in the results.Critical Care    Vol 10 No 2    Winck et al.
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Finally, a search for potential publication bias was performed
using funnel plots and the rank correlation test of Begg. Using
these methods, it is not possible to rule out the hypothesis of
publication bias in our meta-analysis. We found some evi-
dence indicating that smaller studies are more likely to be pub-
lished if they have larger effects and some evidence of a
publication bias favoring the publication of studies with posi-
tive results for NPPV therapy when compared to CPAP. We
should remember, though, that the rank correlation test of
Begg has low power. It is also important to emphasize that the
asymmetry found in funnel plots could be related to several
other sources of bias, and is not necessarily evidence of pub-
lication bias.
Conclusion
The evidence for the advantage of non-invasive ventilation
techniques, and especially of CPAP, over SMT is now robust,
and its use as a first line intervention in ACPE patients is
becoming mandatory. Although one recent guideline for the
treatment of ACPE suggests CPAP to avoid ETI and mechan-
ical ventilation [71], this technique is still underused in many
clinical centers, partly because the clinical questions we
address in this meta analysis had not been answered.
Although both techniques, CPAP and NPPV, showed similar
efficacy in decreasing need for ETI and mortality without
increasing the risk of AMI, from a practical point of view CPAP
has been shown to be cheaper and easier to use and imple-
ment in clinical practice [53], so it could be considered the
preferred intervention in ACPE patients.
Finally, we think it is important for researchers in this field to
create consensus guidelines over methods for reporting and
defining population, interventions and outcome measures.
Taking into account the evidence presented here, it does not
seem advisable, from an ethical point of view, to pursue further
research comparing non-invasive ventilation methods with
SMT in ACPE patients. Research in the future should concen-
trate on the definition of subgroups of patients for whom NPPV
could eventually have advantage over CPAP, the optimal levels
of pressure when using NPPV and definition of the best time
to start non-invasive ventilation.
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